Coqui-pharma solving the impending global shortage of molybdenum -99

International Conference on Nuclear Medicine & Radiation Therapy

July 14-15, 2016 Cologne, Germany

Carmen I Bigles

Coqui Pharma, USA

Keynote: J Nucl Med Radiat Ther

Abstract :

Coqu�­ Radio Pharmaceuticals Corp. is a medical isotope company dedicated to the production of Molybdenum-99, which is used in 20 million procedures each year in the U.S. The Puerto Rican company is based in Coral Gables, Fla., with the mission to bring the foremost medical isotope production facility to the Western Hemisphere and to create a commercially scalable, reliable supply of medical diagnostic and therapeutic radioisotopes in the U.S. This presentation will give an overview of the medical isotope 99Mo and its uses in modern medicine and explore the potential effects of an impending global shortage as nuclear reactors around the world begin to go offline. Carmen will give a thorough overview of Coqu�­ Pharma and its mission to solve the impending shortage crisis as well as explain the technology the firm will employ at its medical isotope production facility.

Biography :

Carmen I Bigles is CEO of Coquí Radio Pharmaceuticals, Corp. a company with the goal of establishing a medical radioisotope production facility in the U.S. As co-owner of Caribbean Radiation Oncology Center, she learned that many patients were being misdiagnosed due to a global shortage of 99Mo. She sought to learn more about the Mo-99 industry and ultimately decided to establish a domestic source of the isotope. She earned a Bachelor’s degree in Mathematics from Inter-American University in San Juan and subsequently her Master’s degrees in architecture and suburban and town planning from the University of Miami.

Email: cbigles@coquipharma.com